PET may be combined with tomography imaging in the presence of the 18 kDa translocator protein (TSPO) biomarker to detect microglial activation in MS, which provides an avenue to explore the pathophysiological outcomes of slow-burning lesions [286,287]. This evidence concerns the gene TSPO and myeloid sarcoma.